This study reveals a novel mechanism by which IPA improves bronchopulmonary dysplasia by targeting VAMP8-mediated autophagosome-lysosome fusion, offering innovative experimental design strategies for metabolic intervention in bronchopulmonary dysplasia.
Literature Overview
The article titled "Indole-3-Propionic Acid Improves Alveolar Development Impairment via Targeting VAMP8-mediated SNAREs Complex Formation in Bronchopulmonary Dysplasia," published in the journal Advanced Science, systematically investigates the protective effects and molecular mechanisms of the tryptophan metabolite IPA in bronchopulmonary dysplasia (BPD). By integrating clinical cohorts, animal models, and molecular interaction experiments, the study demonstrates that IPA directly binds to VAMP8, inhibiting its phosphorylation and promoting the completion of autophagic flux, thereby alleviating hyperoxia-induced alveolar developmental impairment. This work not only expands our understanding of metabolic dysregulation in BPD but also identifies potential therapeutic targets for perinatal lung injury.Background Knowledge
Bronchopulmonary dysplasia (BPD) is the most common chronic lung disease in preterm infants, characterized pathologically by disrupted alveolarization, closely associated with alveolar epithelial type II cell (AEC II) injury, increased apoptosis, and impaired epithelial transdifferentiation. Currently, there are no effective clinical treatments available, with care limited to supportive therapy, highlighting an urgent need to identify druggable molecular targets. Recent studies suggest that amino acid metabolism abnormalities, particularly dysregulation of the tryptophan metabolic pathway, may play a critical regulatory role in BPD. Among these metabolites, indole-3-propionic acid (IPA), derived from gut microbiota, exhibits antioxidant, anti-inflammatory, and neuroprotective properties, though its function in lung development remains unclear. Previous evidence indicates that autophagy dysfunction leads to AEC II homeostasis imbalance, while the SNARE complex—composed of STX17, SNAP29, and VAMP8—acts as a key molecular switch regulating autophagosome-lysosome fusion. Phosphorylation of VAMP8 can block assembly of this complex, thereby halting autophagic flux, yet how this process is precisely regulated remains incompletely understood. This study builds on metabolomic findings showing significant downregulation of IPA in both BPD patients and animal models, leading to the hypothesis that IPA may restore autophagic flux by targeting VAMP8 and thereby improve alveolar development.
Research Methods and Experiments
The study utilized C57BL/6J mice to establish a hyperoxia-induced BPD model, with neonatal pups exposed to 85% oxygen for 14 days to mimic preterm infant lung injury. Plasma samples from preterm infants were collected for targeted metabolomic analysis to validate changes in IPA levels in BPD-affected children. In vitro experiments employed the MLE-12 cell line, subjected to hyperoxic conditions to simulate AEC II injury, with the effects of IPA on cell proliferation, viability, and mitochondrial membrane potential assessed using CCK-8, EdU, flow cytometry, and JC-1 probes. To investigate the mechanism of IPA action, the authors used Western blotting, immunofluorescence, transmission electron microscopy (TEM), and a GFP-mCherry-LC3B dual-fluorescence system to evaluate autophagic flux. Molecular docking, surface plasmon resonance (SPR), and co-immunoprecipitation were performed to confirm the direct binding of IPA to VAMP8 and its regulatory effect on phosphorylation. The experimental design was rigorous, with multi-level validation of IPA’s functional and mechanistic roles.Key Conclusions and Perspectives
Research Significance and Prospects
This study is the first to link IPA with the regulation of VAMP8 phosphorylation, proposing a 'metabolite-kinase-autophagy' axis as a new therapeutic pathway for BPD, providing a theoretical foundation for developing nutritional or pharmacological strategies based on tryptophan metabolism. Targeting VAMP8 phosphorylation may become a universal strategy to alleviate alveolar developmental impairment, particularly in neonates with autophagy deficiencies.
From a translational medicine perspective, IPA—being a natural gut-derived metabolite—has high safety and strong clinical translation potential. Future studies could explore the feasibility of oral IPA supplementation in preterm infants and develop more stable analogs. Moreover, VAMP8 phosphorylation status could serve as a potential biomarker for assessing BPD risk or treatment response.
Conclusion
This study systematically elucidates the protective mechanism of the tryptophan metabolite IPA in bronchopulmonary dysplasia (BPD), revealing that IPA directly targets VAMP8, inhibits its phosphorylation, and promotes SNARE complex formation, thereby restoring autophagosome-lysosome fusion and alleviating AEC II injury and alveolar developmental impairment. This finding not only deepens our understanding of the relationship between metabolic reprogramming and autophagy dysfunction in BPD but also highlights the therapeutic potential of IPA as an endogenous metabolic regulator. From bench to bedside, this research offers a novel perspective for lung protection strategies in preterm infants, suggesting that nutritional interventions or small-molecule modulation of VAMP8 activity may become important approaches for preventing or treating BPD. Future studies should focus on the dynamic changes and safety profile of IPA in preterm infants, accelerating its translational application in neonatal intensive care units (NICUs), with the potential to reshape BPD care systems.
